Literature DB >> 30276103

The Efficacy of Liposomal Bupivacaine in Lumbar Spine Surgery.

Luke Brown1, Tristan Weir1, Mark Shasti1, Omer Yousaf1, Imran Yousaf1, Oliver Tannous1, Eugene Koh1, Kelley Banagan1, Daniel Gelb1, Steven Ludwig1.   

Abstract

BACKGROUND: Postoperative pain management in spine surgery holds unique challenges. The purpose of this study is to determine if the local anesthetic liposomal bupivacaine (LB) reduces the total opioid requirement in the first 3 days following posterior lumbar decompression and fusion (PLDF) surgery for degenerative spondylosis.
METHODS: Fifty patients underwent PLDF surgery in a prospective randomized control pilot trial between August 2015 and October 2016 and were equally allocated to either a treatment (LB) or a control (saline) group. Assessments included the 72-hour postoperative opioid requirement normalized to 1 morphine milligram equivalent (MME), visual analog scale (VAS), and hospital length of stay.
RESULTS: LB did not significantly alter the 72-hour postoperative opioid requirement compared to saline (11.6 vs. 13.4 MME, P = .40). In a subgroup analysis, there was also no significant difference in opioid consumption among narcotic-naive patients with either LB or saline. Among narcotic tolerant patients, however, opioid consumption was higher with saline than LB (20.6 MME vs. 13.3 MME, P = .048). Additionally, pre- and postoperative VAS scores and hospital length of stay were not significantly different with either LB or saline.
CONCLUSIONS: In the setting of PLDF surgery, LB injections did not significantly reduce the consumption of opioids in the first 3 postoperative days, nor did the hospital length of stay or VAS pain scores, compared to saline. However, LB could be beneficial in reducing the consumption of opioids in narcotic-tolerant populations. LEVEL OF EVIDENCE: 2.

Entities:  

Keywords:  degenerative spondylosis; liposomal bupivacaine; lumbar decompression and fusion; opioid; postoperative pain

Year:  2018        PMID: 30276103      PMCID: PMC6159630          DOI: 10.14444/5052

Source DB:  PubMed          Journal:  Int J Spine Surg        ISSN: 2211-4599


  30 in total

1.  A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplasty.

Authors:  Kenneth Bramlett; Erol Onel; Eugene R Viscusi; Kevin Jones
Journal:  Knee       Date:  2012-01-28       Impact factor: 2.199

2.  A prospective randomized double-blind trial of the use of intrathecal fentanyl in patients undergoing lumbar spinal surgery.

Authors:  Jason H H Chan; Giles N A Heilpern; Iain Packham; Ravi K Trehan; Gavin D J Marsh; Aston A Knibb
Journal:  Spine (Phila Pa 1976)       Date:  2006-10-15       Impact factor: 3.468

Review 3.  The treatment of degenerative lumbar disorders. A critical review of the literature.

Authors:  T A Zdeblick
Journal:  Spine (Phila Pa 1976)       Date:  1995-12-15       Impact factor: 3.468

Review 4.  Lumbar Fusion for Degenerative Disease: A Systematic Review and Meta-Analysis.

Authors:  Daniel Yavin; Steven Casha; Samuel Wiebe; Thomas E Feasby; Callie Clark; Albert Isaacs; Jayna Holroyd-Leduc; R John Hurlbert; Hude Quan; Andrew Nataraj; Garnette R Sutherland; Nathalie Jette
Journal:  Neurosurgery       Date:  2017-05-01       Impact factor: 4.654

5.  Liposomal Bupivacaine Use in Transversus Abdominis Plane Blocks Reduces Pain and Postoperative Intravenous Opioid Requirement After Colorectal Surgery.

Authors:  Audrey L Stokes; Sanjib D Adhikary; Ashley Quintili; Frances J Puleo; Christine S Choi; Christopher S Hollenbeak; Evangelos Messaris
Journal:  Dis Colon Rectum       Date:  2017-02       Impact factor: 4.585

6.  A comprehensive multimodal pain treatment reduces opioid consumption after multilevel spine surgery.

Authors:  Ole Mathiesen; Benny Dahl; Berit A Thomsen; Birgitte Kitter; Nan Sonne; Jørgen B Dahl; Henrik Kehlet
Journal:  Eur Spine J       Date:  2013-05-17       Impact factor: 3.134

7.  Nonsteroidal antiinflammatory drugs for postoperative pain management after lumbar spine surgery: a meta-analysis of randomized controlled trials.

Authors:  Kitti Jirarattanaphochai; Surachai Jung
Journal:  J Neurosurg Spine       Date:  2008-07

8.  Relationship between potential opioid-related adverse effects and hospital length of stay in patients receiving opioids after orthopedic surgery.

Authors:  Laura T Pizzi; Richard Toner; Kathleen Foley; Erin Thomson; Wing Chow; Myoung Kim; Joseph Couto; Marc Royo; Eugene Viscusi
Journal:  Pharmacotherapy       Date:  2012-05-08       Impact factor: 4.705

9.  Opioid-related adverse drug events in surgical hospitalizations: impact on costs and length of stay.

Authors:  Gary M Oderda; Qayyim Said; R Scott Evans; Gregory J Stoddard; Jim Lloyd; Kenneth Jackson; Dale Rublee; Matthew H Samore
Journal:  Ann Pharmacother       Date:  2007-03-06       Impact factor: 3.154

Review 10.  Pain management following spinal surgeries: An appraisal of the available options.

Authors:  Sukhminder Jit Singh Bajwa; Rudrashish Haldar
Journal:  J Craniovertebr Junction Spine       Date:  2015 Jul-Sep
View more
  3 in total

1.  Liposomal bupivacaine in posterior spine surgery: A piece of the puzzle for postoperative pain.

Authors:  D Alex Forrester; Harrison Miner; Cameron Shirazi; Niranjan Kavadi
Journal:  J Orthop       Date:  2022-07-12

Review 2.  Postoperative pain treatment after spinal fusion surgery: a systematic review with meta-analyses and trial sequential analyses.

Authors:  Anja Geisler; Josephine Zachodnik; Kasper Køppen; Rehan Chakari; Rachid Bech-Azeddine
Journal:  Pain Rep       Date:  2022-04-27

3.  Multi-modal pain control regimen for anterior lumbar fusion drastically reduces in-hospital opioid consumption.

Authors:  Yoji Ogura; Jeffrey L Gum; Portia Steele; Charles H Crawford; Mladen Djurasovic; R Kirk Owens; Joseph L Laratta; Eric Davis; Morgan Brown; Christy Daniels; John R Dimar; Steven D Glassman; Leah Y Carreon
Journal:  J Spine Surg       Date:  2020-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.